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Mutations in genes encoding subunits of the phagocyte NADPH oxidase complex are
recognized to cause chronic granulomatous disease (CGD), a severe primary immunodefi-
ciency. Here we describe how deficiency of CYBC1, a previously uncharacterized protein in
humans (C17orf62), leads to reduced expression of NADPH oxidase’s main subunit (gp91phox)
and results in CGD. Analyzing two brothers diagnosed with CGD we identify a homozygous
loss-of-function mutation, p.Tyr2Ter, in CYBC1. Imputation of p.Tyr2Ter into 155K chip-
genotyped Icelanders reveals six additional homozygotes, all with signs of CGD, manifesting
as colitis, rare infections, or a severely impaired PMA-induced neutrophil oxidative burst.
Homozygosity for p.Tyr2Ter consequently associates with inflammatory bowel disease (IBD)
in Iceland (P= 8.3 × 10−8; OR= 67.6), as well as reduced height (P= 3.3 × 10−4; −8.5 cm).
Overall, we find that CYBC1 deficiency results in CGD characterized by colitis and a distinct
profile of infections indicative of macrophage dysfunction.
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Chronic granulomatous disease (CGD) is a rare primaryimmunodeficiency characterized by severe recurrent bac-terial and fungal infections, along with manifestations of
chronic granulomatous inflammation1. The incidence of the
disease varies significantly worldwide, from around 1 in 200,000
in North America and Europe, to 1 in 70,000 in the Israeli Arab
population2. CGD results from an impaired ability of phagocytes
to mount a burst of reactive oxygen species (ROS) in response to
pathogens2. The production of ROS is catalyzed by a multi-
protein enzymatic complex, known as the NADPH oxidase
complex3. A majority of CGD patients carry pathogenic geno-
types in one of five genes encoding subunits of the phagocyte
NADPH oxidase; either X-linked recessive mutations in CYBB, or
autosomal recessive mutations in CYBA, NCF1, NCF2, or
NCF42,4–6. Patients with X-linked recessive mutations in CYBB
are generally recognized to have the most severe disease course
with earlier age at onset, whereas patients with autosomal
recessive mutations in NCF1 show a significantly higher age at
onset1,2,7. In a recent review of NCF4 mutations, the clinical
presentation of NCF4-deficient patients is described as being even
more distinct, resembling a mild, atypical form of CGD6.
For the purpose of searching for associations between variants
in the sequence and phenotypes, we have whole-genome
sequenced (WGS) 37K Icelanders and genotyped 155K, a large
fraction of the Icelandic population (11 and 46% of 338K,
respectively)8–10. This dataset allows for accurate detection of
genotypes down to a frequency of 0.01% in all 155K8,9. Moreover,
by serving as a population reference, the set is proving instru-
mental for genetic analysis of rare diseases in the clinical
setting8,11,12.
Through WGS of two brothers diagnosed with CGD, we
identify a homozygous loss-of-function mutation, p.Tyr2Ter, in
CYBC1 (previously C17orf62). In our existing set of sequenced
and chip-genotyped Icelanders we find six additional homo-
zygous individuals. Genotype-based recall confirms that all eight
homozygotes have signs of CGD, manifesting as colitis, rare
infections, or a severely impaired PMA-induced neutrophil oxi-
dative burst. We show that homozygosity for p.Tyr2Ter results in
complete loss of CYBC1, and reduced expression of gp91phox,
NADPH oxidase’s main subunit, leading to an impaired oxidative
burst. Our results indicate that CYBC1 is essential for successful
formation of the NADPH oxidase complex, likely by acting as a
chaperone. An excess of colitis in the group of homozygotes, as
well as a distinct profile of infections, suggests that CYBC1
deficiency has a more pronounced effect on macrophages. In
summary, by leveraging an extensive population database we
elucidate the role of a previously uncharacterized gene in humans
and identify a novel cause of CGD.
Results
Analysis of two brothers diagnosed with CGD. We were pre-
sented with two Icelandic brothers diagnosed with CGD (indi-
viduals A and B, Fig. 1a and Table 1), to search for the causal
mutation through WGS. The brothers were initially diagnosed
with Crohn’s disease (CD), at 7 and 9 years of age, after devel-
oping severe diarrhea with intestinal biopsies showing granulo-
matous lesions compatible with CD. The younger brother had
developed episodes of acute lymphadenitis and inflammation of
the orbit at the ages of 5 and 6 years, respectively. Both brothers
experienced recurrent bacterial infections, including infections
around the nose and an active wound infection in the mouth,
from which the opportunistic bacterium Burkholderia cepacia was
cultured. B.cepacia is known to cause infections in immuno-
compromised hosts, in particular CGD patients4. At this stage,
the combined clinical, histological, and bacteriological evidence
led to a suspicion of CGD. A formal CGD diagnosis was subse-
quently confirmed for both brothers based on PMA-induced
neutrophil oxidative burst tests at the time (Fig. 1b). The number
of infections reported for the brothers was nonetheless somewhat
less than what would be expected in X-linked CGD patients. The
brothers’ gastrointestinal symptoms did not respond to conven-
tional treatment for Crohn’s disease, and were the main reason
for them undergoing hematopoietic stem cell transplantation
(HSCT) at 17 (individual A) and 18 (individual B) years of age.
The older brother (individual B) died of post-HSCT complica-
tions; whereas, the younger brother (individual A) was success-
fully transplanted in 2010 and has been symptom-free since then
(see Supplementary Note 1 for full clinical description).
We sequenced the whole genomes of the two brothers (DNA
samples taken pre-HSCT), hereafter referred to as the probands,
their three unaffected siblings and parents (see pedigree Fig. 1a,
and Methods section). We found no rare coding or splice-site
mutations in the five genes known to harbor mutations causing
CGD (all five genes were well-covered in the probands’ sequence
data, Supplementary Table 1). Previously, we had identified a
known mutation in CYBA13 in Iceland (NP_000092.2:p.
Arg90Trp, MAF= 0.58%), under a recessive mode of inheritance.
We found five Icelanders homozygous for that mutation (out of
155K chip-genotyped), two were diagnosed with CGD, and three
had a clinical profile consistent with CGD (Supplementary
Table 2). Importantly, WGS followed by Sanger sequencing
verified the absence of this CYBA mutation from the two
probands. We subsequently expanded our analysis to the coding
and splicing regions of all RefSeq genes (n= 18,570). Due to the
rarity of the disease and high penetrance of known CGD
mutations we focused on rare genotypes, defined using our
reference set of the Icelandic population (37,260 individuals WGS
to a median depth of 38×). We selected heterozygous genotypes
with a minor allele frequency (MAF) below 0.05%, excluding
genotypes carried by either of the two unaffected parents, and
homozygous/compound heterozygous genotypes where variants
had a MAF below 2%, including both X-linked and autosomal
genotypes. We found two genotypes fulfilling these criteria, in
genes not previously known to cause Mendelian disease. One of
these, a homozygous missense mutation in GCGR encoding the
human glucagon receptor (NM_000160.3:c.449G>A; NP_000151.1:
p.Ser150Asn; hg38 position chr17:81,811,277; MAF= 0.33%), was
dismissed based on lack of biological relevance (Supplementary
Note 2). The other corresponds to a predicted complete knockout, a
homozygous stop-gained mutation, p.Tyr2Ter, in CYBC1
(NM_001033046.3:c.6C>G; NP_001028218.1:p.Tyr2Ter; hg38 posi-
tion chr17:82,449,249; MAF= 0.76%). Prior to our application for
the gene symbol CYBC1, it was known under the placeholder
symbol C17orf62. The brothers are the only members of their family
homozygous for CYBC1 p.Tyr2Ter, their parents and two
unaffected siblings are heterozygous carriers, and their third sibling
a non-carrier (all confirmed by Sanger sequencing). CYBC1 shares
89% amino acid sequence identity with the murine bc017643 which
was recently shown to be essential for ROS production14, consistent
with the reduced ROS production described for CGD patients. Both
neutrophils and BM-derived macrophages from bc017643-knockout
mice showed a highly impaired oxidative burst in response to a
range of stimuli, including PMA. Accordingly, bc017643-knockout
mice (-/-) showed high susceptibility to bacterial infections,
evidenced by Listeria monocytogenes and Salmonella enterica
serovar Typhimurium infections14. Interestingly, while macro-
phages from the bc017643-knockout mice had a similar ROS deficit
as macrophages from gp91phox/Cybb-deficient mice, neutrophils
from the bc017643-knockout mice showed some ROS generation
whereas neutrophils from the gp91phox/Cybb-deficient mice did
not14.
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The availability of population level data allowed us to search
for other individuals homozygous for CYBC1 p.Tyr2Ter. Out of a
learning set of 28,075 WGS Icelanders we detected two other
homozygous individuals, as well as 372 heterozygous carriers of
the mutation. This allowed for accurate imputation (Methods
section) of the mutation into our set of 155K chip-genotyped
Icelanders based on long-range haplotype sharing8 (imputation
information= 0.99). Through imputation we found four addi-
tional individuals homozygous for p.Tyr2Ter, and confirmed
their genotypes with Sanger sequencing.
Colitis and rare infections in p.Tyr2Ter homozygotes. To
investigate the consequences of CYBC1 p.Tyr2Ter, we searched
for pathological manifestations in these six additional homo-
zygotes and found that three had colitis, like the two probands,
and had received a diagnosis of inflammatory bowel disease (IBD)
(Table 1). Intestinal inflammation is a common manifestation of
CGD and around 40% of CGD patients develop CD-like pro-
blems15. Of the three additional homozygotes suffering from
colitis, two had a confirmed granulomatous colitis (individuals C
and F). Individual C was initially diagnosed with ulcerative colitis
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Fig. 1 Pedigree and burst test results for the two probands, and the CYBC1 protein. a Pedigree of the two CGD brothers showing their CYBC1 p.Tyr2Ter
genotypes. Squares represent males, circles represent females, and a slashed symbol indicates a deceased individual. Filled symbols represent affected
individuals; the two affected are referred to as individuals A and B in the manuscript. The genotype of the p.Tyr2Ter mutation (NP_001028218.1:p.Tyr2Ter;
NM_001033046.3:c.6C>G; hg38 position chr17:82,449,249) is indicated with M and W, M representing the mutated allele and W the wild type. M/M
therefore indicates homozygous status, W/M indicates heterozygous status and W/W a non-carrier. b Neutrophil oxidative burst test for the two CGD
brothers homozygous for CYBC1 p.Tyr2Ter (individuals A and B) and their controls, test was performed pre-HSCT. Left panel shows fluorescent peaks for
unstimulated and PMA stimulated neutrophils from the controls, and the right panel shows peaks for unstimulated and PMA stimulated neutrophils from
the two homozygous brothers. Negative and positive cells are defined by setting a gate for unstimulated cells. Neutrophils from individuals A and B failed to
generate an oxidative burst equivalent to their controls, their respective stimulation indices were SIA= 1.34 and SIB= 2.50. c Topological prediction of
CYBC1 (NP_001028218.1)28. CYBC1 is predicted to be a transmembrane protein, spanning the lipid bilayer via two transmembrane regions (aa 21–39 and
aa 45–63). A red diamond represents the p.Tyr2Ter mutation at the second amino acid of the protein
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(UC), receiving a CD diagnosis only after undergoing total
colectomy that revealed extensive granulomatous inflammation of
the colon. The third individual, individual E, was diagnosed at 14
years of age with total colitis. Repeated biopsies from colon did
not yield granulomatous changes. However, even though granu-
lomas were not observed in individual E, his clinical course could
be considered to better fit CD than UC. Notably, granulomatous
changes are unconfirmed in the majority of CGD patients with
colitis16. Furthermore, diffuse colitis involving all regions of the
colon, as seen for individual E, could be considered characteristic
of the gastrointestinal involvement in CGD16. As expected, p.
Tyr2Ter associates with IBD in Iceland under the recessive model
(P= 8.3 × 10−8; OR (95% CI)= 67.6 (14.5, 315.5); ncases= 2429;
ncontrols= 338,647; likelihood ratio test; Supplementary Table 3).
Limiting to chip-typed individuals, we found that heterozygous
carriers of p.Tyr2Ter were not at a significantly higher risk of IBD
than non-carriers (P= 0.31; OR (95% CI)= 1.21 (0.84, 1.75);
ncases= 1701; ncontrols= 135,106; likelihood ratio test).
To gather additional clinical and biological information we
attempted genotype-based recall of p.Tyr2Ter homozygotes for
phenotyping. We obtained additional hospital-based information
(including discharge diagnoses and laboratory measurements, see
Table 1 and Methods section), and found that seven out of eight
homozygotes had experienced severe and/or early-onset bacterial
or fungal infections (including the two probands). Individual D
was the only one not to have reported any severe infections, at 30
years of age. In patients with CGD, microbial catalase is
traditionally recognized as the most important virulence factor
in infections17. Consistent with this, many of the infections noted
in the homozygous individuals were caused by catalase-positive
pathogens, including a mucous membrane infection by Burkhol-
deria cepacia2, candidal septicemia (Candida albicans18), Legion-
naires’ disease (Legionella19), and miliary tuberculosis
(Mycobacterium tuberculosis20). The rarity of most of these
infections is notable, only 61 occurrences of Legionella infections
have been reported in Iceland between 1997 and 2017, and only
19 individuals have been diagnosed with candidal septicemia over
the same period21. Thus, it is noteworthy that individual A
developed both Legionnaires’ disease and candidal septicemia.
Similarly, only 55 occurrences of miliary tuberculosis have been
noted in Iceland, including individual H (out of 11,438
tuberculosis cases, diagnosed between 1901 and 198922).
Individual G had invasive pneumococcal disease at 30 years of
age caused by Streptococcus pneumoniae7, and later developed
interstitial pulmonary fibrosis, a noted complication of the
exaggerated inflammatory response in CGD2,23,24.
In terms of microbe spectrum, the overall infectious profile of
the homozygous individuals could be considered somewhat
unusual for CGD. The invasive fungal sepsis by C.albicans, and
the miliary tuberculosis by M.tuberculosis are characteristic of
CGD, as well as the pneumonia episodes reported for individual
A (at 14 years of age, registered as Legionnaires’ disease, and
again at 16 years of age). However, the pathogens cultured from
the pneumonia episodes are only sporadically reported in
CGD (Legionella1,25 and S.pneumoniae7), and the absence of
some of the most frequently encountered pathogens in CGD,
such as Staphylococcus aureus and Aspergillus species, is
noteworthy2,7.
Table 1 Phenotypes of eight CYBC1 p.Tyr2Ter homozygous individuals
ID Sex YOB/D GI symptoms Burst testa Heightb Infections Immunological






Abnormala 172 (18) Legionnaires‘ disease, Legionella (14);
Local infections of skin,
subcutaneous tissue (repeated);
Viral infection (12);
Accute suppurative otitis media (22)
Acute inflammation of orbit (6);








furuncle and carbuncle of
buttock (16)
Abnormala 162 (17) Bacterial intestinal infection, C.
difficile (16);
Candidal septicaemia, C.albicans (18);
Viral intestinal infection (16);
Suppurative otitis media (6)
Hepatosplenomegaly (17);
Acute pancreatitis (18)
C M 1985 CD (12);
Anal fissures (4, 7);
Anal abscess (11)
ND 180 (25) — —
D F 1985 — Abnormala 159 (30) Herpese (25) RF positive (21);
Eczemae
E M 1980 UC (14) ND 178 (37) Onychomycosis (repeated) —






Chronic nephritic syndrome (26)
G F 1955/
2015
— ND 159 (50) Invasive pneumococcal disease, S.
pneumoniae (positive blood culture)
(30)
Interstitial pulmonary disease with
fibrosis (56)
H F 1940 — ND 156 (55) Miliary tuberculosis, M.tuberculosis
(13)
—
Figures in parentheses () denote age at diagnosis or measurement, in years
YOB/D year of birth/death (rounded by 5 years for individuals C–H), GI gastrointestinal, CD Crohn’s disease, UC ulcerative colitis, CGD chronic granulomatous disease, ND not determined, RF rheumatoid
factor
aBurst test for individual A and B was performed in 2008, burst test for individual D was performed in 2017
bAll heights are given in cm. Average and SD for height of Icelandic males and females is 178.8 ± 6.9 cm and 165.6 ± 6.3 cm, respectively35
cIndividuals A and B are brothers, presented in Fig. 1
dIndividuals B and F underwent total colectomy
eSelf-reported phenotypes (via an online questionnaire)
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In addition to the two probands, we performed WGS for the
six other CYBC1 p.Tyr2Ter homozygotes. The five individuals
with gastrointestinal involvement were analyzed for variants
previously known to cause monogenic IBD15,26, and the absence
of such variants confirmed. Additionally, no known or expected
pathogenic variants were detected in other known CGD genes in
any of the eight p.Tyr2Ter homozygotes. Consistent with the
effect of other known CGD genotypes on stature4 we also found
that homozygosity for p.Tyr2Ter associates with reduced height
(P= 3.3 × 10−4; effect (95% CI)=−1.24 SD (−1.92, −0.56)/
−8.5 cm; likelihood ratio test; Supplementary Tables 3 and 4).
Taking all of the above into consideration, we conclude that the
clinical presentation of seven out of eight homozygous individuals
(all but D) is suggestive of CGD.
Functional consequences of p.Tyr2Ter. CYBC1 encodes a 187
amino acid protein (NP_001028218.1, canonical as defined by
RefSeq), highly expressed in whole blood14,27. It is predicted to be
a transmembrane protein, spanning the lipid bilayer via two
transmembrane regions (Fig. 1c)28. The p.Tyr2Ter mutation
introduces a premature termination codon at the second amino
acid of the protein, preventing translation of the full-length
protein. We observed no reduction in CYBC1 mRNA expression
in white blood cells from heterozygous carriers of p.Tyr2Ter
(ncarriers= 29; nnon-carriers= 2430; P= 0.86; Effect (95% CI)= 0.03
SD (−0.36, 0.30), Supplementary Fig. 1), nor did we observe any
signs of allelic imbalance when assessing allele-specific expression
(Supplementary Fig. 2). This indicates that p.Tyr2Ter does not
lead to nonsense-mediated mRNA decay (NMD), consistent with
NMD being less efficient when premature termination codons
occur in such close proximity to the start codon29. Rather, we
expect p.Tyr2Ter to result in a lack of product at the protein level.
We investigated the possibility of an alternative start codon in
CYBC1 producing a functional protein. The closest codon for
methionine following the same reading frame as p.Tyr2Ter occurs
in exon 6 (out of 7 exons). The non-coding mRNA corresponding
to this start codon (NR_036518, expressed in whole blood27)
encodes a sequence of 63 amino acids, lacking the two membrane-
spanning domains of CYBC1.
To study the direct effect of p.Tyr2Ter at the protein level, we
performed western blot analysis on available lymphocytes from
four heterozygous carriers of p.Tyr2Ter, revealing 53% less
CYBC1 protein than in matched non-carriers (Fig. 2a). Addi-
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Fig. 2 Effect of p.Tyr2Ter on CYBC1, the neutrophil oxidative burst, and gp91phox. a CYBC1 protein expression, relative to ACTIN, in lymphocytes from
CYBC1 p.Tyr2Ter homozygous individuals D and F (triangles), four heterozygous carriers (squares), and matched (age and sex) non-carriers (circles).
CYBC1 expression was not detected in the homozygous individuals in contrast to their matched non-carriers, and was reduced by 53% in the heterozygous
carriers, compared to matched non-carriers. The analysis was performed by western blot (shown in Supplementary Fig. 3 and 4), where ACTIN was used
as a loading control. b Neutrophil oxidative burst test for CYBC1 p.Tyr2Ter homozygous individual D and her matched (age and sex) non-carrier. Left panel
shows fluorescent peaks for unstimulated and PMA stimulated neutrophils from the non-carrier, and the right panel shows peaks for unstimulated and
PMA stimulated neutrophils from homozygous individual D. Negative and positive cells are defined by setting a gate for unstimulated cells. Neutrophils
from individual D failed to generate an oxidative burst equivalent to her matched non-carrier, the stimulation index for homozygous individual D was SID=
2.35. c Protein expression of gp91phox, relative to ACTIN, in monocyte-derived macrophages from CYBC1 p.Tyr2Ter homozygotes D and F (squares) and
their matched (age and sex) non-carriers (circles). gp91phox expression was absent in the two homozygotes in contrast to their matched non-carriers. The
analysis was performed by western blot (shown in Supplementary Fig. 5), where ACTIN was used as a loading control. d CYBC1 and gp91phox expression in
fresh neutrophils from CYBC1 p.Tyr2Ter homozygous individual D and her matched (age and sex) non-carrier. CYBC1 expression was not detected in the
homozygous individual in contrast to the non-carrier. gp91phox expression was ~50% lower in the homozygote than her matched non-carrier. The analysis
was performed by western blot, and ACTIN was used as a loading control
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samples from two p.Tyr2Ter homozygotes (individuals D and F,
Table 1). We found no trace of the full-length CYBC1 protein in
lymphocytes from the two homozygotes (Fig. 2a).
Chaperone for cytochrome b-245. The oxidative burst consists of
a rapid production and release of ROS, a process catalyzed by the
NADPH oxidase complex3. The phagocyte NADPH oxidase is
composed of six subunits, three cytosolic components (p47phox,
p67phox, and p40phox), a regulatory G-protein (Rac1/Rac2) and an
essential membrane-bound heterodimer (gp91phox-p22phox),
known as cytochrome b-245, which mediates the transfer of
electrons to oxygen3. The dimerization of gp91phox and p22phox is
a relatively inefficient process, and as unassembled monomers the
two proteins quickly undergo degradation14,30,31. Neutrophils and
bone marrow (BM)-derived macrophages from bc017643-knock-
out mice had markedly reduced expression of both gp91phox and
p22phox, despite expressing normal mRNA levels for these pro-
teins, most likely due to the role of bc017643 as a chaperone in the
dimerization of cytochrome b-245. The cytosolic components of
NADPH oxidase (p47phox, p67phox, and p40phox) were not dif-
ferentially expressed in bc017643-deficient mice14. To determine
whether a similar role could be expected for CYBC1 in humans,
we measured gp91phox in monocyte-derived macrophages and
neutrophils from p.Tyr2Ter homozygotes. We detected no
gp91phox in monocyte-derived macrophages from homozygous
individuals D and F (Fig. 2c), in contrast to matched non-carriers,
and a ~50% reduction in gp91phox levels in neutrophils from
individual D (neutrophils were not available from individual F,
Fig. 2d). Furthermore, we were able to test and confirm an
impaired PMA-induced oxidative burst in neutrophils from
homozygous individual D (Fig. 2b), thereby providing indepen-
dent confirmation of an impaired oxidative burst in a p.Tyr2Ter
homozygote (as observed previously for the two probands,
Fig. 1b). Individual D is therefore positive for the test widely used
as a diagnostic test for CGD without having, to our knowledge,
developed colitis or chronic infections at age 30 (Table 1 and
Methods section). Our findings, together with the prior observa-
tion in mice, suggest a chaperone role for CYBC1 in the dimer-
ization of gp91phox and p22phox in humans. We therefore renamed
the gene CYBC1, for cytochrome b-245 chaperone 1.
The p.Tyr2Ter mutation is absent from 138,632 exomes/
genomes in a large multi-ethnic public database (gnomAD), and
no other coding homozygous loss-of-function mutation is listed
in the canonical transcript on gnomAD32 (Supplementary
Table 5). Nonetheless, we came across a homozygous missense
mutation in CYBC1, p.Asp43Asn (NM_001033046.3:c.127G>A,
hg38 position chr17:82,447,580), in a single case in a recent
publication from Saudi Arabia33. Although the mutation was
classified as a missense, we identified its location to be at the
exonic splice junction where it is predicted to disrupt correct
splicing of the mRNA34. Interestingly, the individual homozygous
for that mutation had symptoms compatible with CGD, including
lymphadenopathy, hepatosplenomegaly, recurrent fever, and
growth retardation33.
Discussion
In summary, among 155K chip-genotyped Icelanders we identi-
fied eight homozygous for a rare loss-of-function mutation, p.
Tyr2Ter, in CYBC1 (previously known as the uncharacterized
C17orf62). The eight homozygotes show signs compatible with
CGD, either gastrointestinal symptoms, rare infections, and/or a
biochemically proven oxidative burst defect.
Impaired expression of gp91phox in p.Tyr2Ter homozygous
individuals, the oxidative burst defect, and prior evidence in
knockout mice all point to CYBC1 as an essential factor for
successful formation of the NADPH oxidase complex. CYBC1 is
known to co-localize and interact with gp91phox in the endo-
plasmic reticulum (ER)14,35, where it likely acts as a chaperone for
dimerization of gp91phox and p22phox (cytochrome b-245).
Although no definitive conclusion can be drawn from only one
individual, the difference in expression of gp91phox between
monocyte-derived macrophages (absent) and neutrophils (50%
reduced) from homozygous individual D is noteworthy, and
suggests the presence of more than one chaperone for cyto-
chrome b-245 in the neutrophil lineage. Consequently, mechan-
isms more specific to macrophages, such as the exaggerated
proinflammatory responses seen in CGD patients36, may be a
more prominent phenotype in CYBC1-deficient individuals. The
complete absence of gp91phox from macrophages is also in line
with some of the infections observed in the p.Tyr2Ter homo-
zygous individuals, like M.tuberculosis37, Legionella38, and C.
albicans39, as well as the increased susceptibility of bc017643-
knockout mice to S.Typhimurium and L.monocytogenes infec-
tions14. CYBC1 deficiency thus appears to predispose to a distinct
spectrum of microbes that can be considered more specific to
macrophages. Supportive of this, a prior study of two distinct
CYBB mutations causing infections restricted to mycobacteria
demonstrated an impaired oxidative burst in macrophages but
not in neutrophils40.
We expect CYBC1 p.Tyr2Ter to have reached its frequency in
Iceland (carried by about 1 in 70) through the founder effect8.
The founder effect allows such mutations to reach a considerable
frequency in the bottlenecked/founder population of Iceland,
resulting in homozygotes in high-enough numbers to confer
statistical power for discovery of disease associations8,41. We have
identified eight p.Tyr2Ter homozygous Icelanders in our dataset,
comprising 155K chip-genotyped individuals, and would expect
19 homozygotes in the entire Icelandic population (338K indi-
viduals). Overall, we observe thirteen Icelanders with a genotype
causing signs compatible with CGD, eight homozygous for
CYBC1 p.Tyr2Ter and five for CYBA p.Arg90Trp. This amounts
to a predicted disease prevalence of 1 in 12,000 in Iceland, much
higher than reported for CGD in the literature2. In addition to the
founder effect in Iceland, this higher overall prevalance of CGD
may be explained by the fact that in some instances the causative
genotypes lead to a mild phenotype resulting in underdiagnosis of
the disease. In Iceland however, we are simply assessing pre-
valence by identifying pathogenic genotypes.
Our results indicate that CYBC1-deficient individuals have
some residual ROS production, similar to what has been reported
for CGD patients with NCF1 biallelic mutations42. Residual ROS
production has been shown to correlate with a milder clinical
presentation, and improved overall survival in CGD depending
on early detection and treatment of the disease42. Our findings
therefore underline the value of using genotypes for the identi-
fication of previously undiagnosed cases. Out of the 13 Icelanders
with a CGD genotype, only the two probands and two of the
CYBA p.Arg90Trp homozygotes were, to our knowledge, diag-
nosed with CGD prior to the discovery of CYBC1. Reporting of
the genotypes of the remaining nine individuals to their treating
physicians is already proving important for their clinical follow-
up and treatment.
The set of 155K chip-genotyped Icelanders used for our study
consists of individuals healthy enough to have survived up to the
time of recruitment, with the vast majority over 18 years old at
the time of sample acquisition (mean age at recruitment is 46
years). The set is therefore biased toward adults, and the identi-
fication of genotypes from such a set can be expected to reveal
greater phenotypic variability than recruitment based on clinical
presentation alone, as is illustrated by our study. The mean age at
onset of symptoms for the five p.Tyr2Ter homozygous
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individuals who had gastrointestinal manifestations is 12.2 years,
and deviates somewhat from X-linked recessive CGD patients, the
vast majority of whom are diagnosed before 5 years of age2. The
CYBC1 p.Tyr2Ter homozygotes also contrast patients with NCF4
biallelic mutations in terms of loss-of-neutrophil NADPH oxidase
activity. The CYBC1-deficient individuals have strongly impaired
PMA-induced neutrophil oxidative burst (stimulation indices
lower than 3, as in X-linked CGD43,44, see Fig. 1b and Fig. 2b),
whereas NCF4-deficient patients have normal or mildly impaired
PMA-induced neutrophil oxidation5,6. We recognize that for full
understanding of the molecular mechanism of CYBC1 deficiency,
a more detailed analysis of NADPH oxidase activity is required,
such as assessment of particle-induced ROS production, as well as
experiments with other cell types.
Previously, we and others have identified and described a large
set of rare complete human knockouts45–48. By systematically
investigating homozygous loss-of-function carriers, we are
beginning to understand how some of these mutations relate to
diseases and other traits. Through genotype-based recall of
individuals homozygous for CYBC1 p.Tyr2Ter, we were able to
confirm the loss-of-function effect of p.Tyr2Ter by verifying the
absence of the CYBC1 protein. Moreover, this allowed us to
demonstrate that complete loss of CYBC1 leads to a reduced
neutrophil oxidative burst in the absence of pathogenic mutations
in known components of the NADPH oxidase complex. Hitherto,
pathogenic mutations in five genes encoding subunits of the
phagocytic NADPH oxidase complex were known to cause CGD.
We have shown that CYBC1 represents a novel player in the
NADPH pathway and the sixth CGD gene.
Methods
Study population and generation of genetic dataset. Our approach to whole-
genome sequencing, genotyping, long-range phasing, and imputation has been
described in detail in previous publications8,9. In brief, 28,075 Icelanders partici-
pating in various disease projects at deCODE genetics were whole-genome
sequenced using standard TrueSeq methodology (Illumina) to a median depth of
37×. Further, 155,250 Icelanders have been genotyped with Illumina microarrays
(chip-genotyped), and genotype probabilites for untyped relatives have been cal-
culated based on Icelandic genealogy. Genotypes of sequence variants identified
through sequencing (SNPs and indels) have been imputed into all chip-typed
Icelanders and their close relatives (familial imputation).
An extension of this learning set of 28,075 WGS Icelanders are 9185 Icelanders
more recently recruited and sequenced, amounting to a set of 37,260 WGS
Icelanders used for the current study. These 37,260 Icelanders were all sequenced
by the same method as previously described, to a median depth of 38×8,9.
All participating individuals who donated blood or buccal tissue samples, or
their guardians, provided written informed consent. All sample identifiers were
encrypted in accordance with the regulations of the Icelandic Data Protection
Authority. Personal identities of the participants and biological samples were
encrypted by a third-party system approved and monitored by the Icelandic Data
Protection Authority. Years of births/deaths in Table 1 of individuals not recruited
through clinical sequencing (individuals C–H) are rounded to five years (pedigrees
are provided in Supplementary Fig. 6). The study was approved by the Data
Protection Authority (ref. 2013030423/ÞS/--, with amendments) and the National
Bioethics Committee (ref. VSN 12–121, VSNb2012070013/03.12), that also
reviewed and approved the protocol, methodology and all documents presented to
the participants. All methods were performed in accordance with the relevant
guidelines and regulations.
Imputation. Imputation is a method for inferring genotypic status of variants that
have not been directly genotyped. Imputation of untyped variants into the mix of
typed variants is now routine in human genetics8. The extensive genealogical
information available for the Icelandic population, along with deCODE’s long-
range phasing of a large set of genotyped Icelanders8,49 has increased imputation
accuracy and speed by removing uncertainty in phasing. In general, a haplotype
can be imputed into an untyped individual if two genotyped relatives share a long
haplotype that is identical by descent (IBD), and the genealogy indicates that the
path of IBD sharing goes through the individual49.
The informativeness of genotype imputation is estimated by the ratio of the
variance of imputed expected allele counts and the variance of the actual allele
counts:
Var E θjchip datað Þð Þ
VarðθÞ ;
where θ is the haplotype allele count. Var(E(θ | chip data)) was estimated by the
observed variance of the allele imputations and Var(θ) was estimated by p(1-p),
where p is the allele frequency. This metric has the property of being 0 when the
imputation is completely uninformative (the same value is always imputed) and 1
when the imputation is fully informative. Asymptotically, the expectation of the
metric equals the r2 between the imputed alleles and the true genotypes.
Whole-genome sequencing of the two probands and their family. Genomic
DNA (gDNA) was isolated from blood samples taken pre-HSCT from the two
affected brothers and from buccal samples taken in 2016 from their parents and
three siblings. A request for whole-genome sequencing (WGS) was sent through an
in-house laboratory information management system (LIMS). gDNA was regis-
tered and isolated by an in-house core facility (Biological Materials facility).
Samples were delivered to the Genome Sequencing Laboratory in a barcoded 96-
well tray format and stored at 4 °C until use. Samples were prepared for sequencing
using the TruSeq PCR-free library preparation kits from Illumina, and sequenced
on Illumina instruments to an average genome-wide coverage of 39×. Details of the
sample preparation, paired-end sequencing, read processing and alignment and
filtering of resulting BAM files have been described in previous publications8,9.
Variant calling, annotation, and filtering. Variants were called using version
2.3–9 of the Genome Analysis Toolkit (GATK)50, reads were called with GATK’s
HaplotypeCaller, version 2014.4-3.3.0-0-ga3711aa, using joint calling. In our ana-
lysis of the WGS data of the two probands we focused on SNPs and small indels
(shorter than 20 base pairs) at coding and splicing regions in their genomes, as
annotated by release 80 of the Variant Effect Predictor51, using RefSeq gene
annotations. We assessed the frequency of observed sequence variants using (1) our
set of 37,260 whole-genome sequenced Icelanders8,9 at a median depth of 38× and
gnomAD32, and (2) 155,250 chip-genotyped Icelanders with 32.5 million imputed
variants. We defined rare autosomal recessive genotypes as homozygous or com-
pound heterozygous sequence variants, each with a minor allele frequency lower
than 2% in our set and gnomAD32. We defined rare autosomal dominant geno-
types as variants with a minor allele frequency lower than 0.05% in our set and
gnomAD.
Association testing. We tested for association between sequence variants and
phenotypes under a recessive mode of inheritance, as previously described52,53. We
used logistic regression to test for association with binary phenotypes, adjusting for
sex, age, and county within Iceland. Quantitative phenotypes were tested using a
linear mixed model implemented in BOLT-LMM54. Height measurements were
corrected for year of birth, sex, and age at measurement, using a rank-based inverse
normal standardization. A total of 31.6 million variants were tested for association
under a multiplicative model. For the recessive analysis, there were 19.2 million
variants with homozygotes for the minor allele in the dataset. All of the variants
that were tested had imputation information over 0.8. The threshold for genome-
wide significance was corrected for multiple testing with a weighted Bonferroni
adjustment using as weights the enrichment of variant classes with predicted
functional impact among association signals55. The significance threshold then
becomes 2.5 × 10−7 for high-impact variants (including stop-gained, frameshift,
splice acceptor or donor), 5.0 × 10−8 for moderate-impact variants (including
missense, splice-region variants and in-frame indels), 4.5 × 10−9 for low-impact
variants, 2.3 × 10−9 for DNase I hypersensitivity site (DHS) variants and 7.5 × 10
−10 for remaining variants.
Phenotypic information. We performed phenotypic assessment of the eight
individuals homozygous for CYBC1 p.Tyr2Ter by (1) examining a large set of
existing clinical, biological, and genealogical information and (2) obtaining novel
phenotypic information through an extensive health study of the Icelandic popu-
lation. The study consists of a 4-h visit with a medical examination, interview and
collection of biological samples. For individuals participating in the study we are
able to review, through a two-way encryption system, hospital-based information,
including hospital discharge diagnoses and laboratory tests. This study allows us to
perform deeper phenotyping for individuals targeted by their genotype (genotype-
based recall). We have attempted genotype-based recall for a set of ~13,000 loss-of-
function homozygous individuals, based on WGS and imputation, and controls45.
Sanger sequencing. The CYBC1 p.Tyr2Ter mutation was submitted to Sanger
sequencing for confirmation of a homozygous genotype in the eight individuals
detected by WGS and chip-genotyping. The position of the p.Tyr2Ter mutation
was also sequenced by the Sanger method in the five family members of the two
probands (Fig. 1a). The CYBA p.Arg90Trp mutation was also submitted to Sanger
sequencing for all eight CYBC1 p.Tyr2Ter homozygous individuals. Primers for
Sanger sequencing were designed using the Primer 3 software56. Following PCR,
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cycle sequencing reactions were performed in both directions on MJ Research
PTC-225 thermal cyclers, using the BigDye Terminator Cycle Sequencing Kit v3.1
(Life Technologies) and Ampure XP and CleanSeq kits (Agencourt) for cleanup of
the PCR products and cycle sequencing reactions. Sequencing products were loa-
ded onto the 3730 XL DNA Analyzer (Applied Biosystems) and analyzed with the
Sequencher 5.0 software (GeneCodes Corporation).
Neutrophil oxidative burst in homozygous individual D. We performed a
neutrophil oxidative burst test for CYBC1 p.Tyr2Ter homozygous individual D
(Table 1). The neutrophil oxidative burst was measured on a fresh whole-blood
sample from individual D with a Phagoburst kit (BD biosciences, #341058) used
according to the manufacturer’s instructions. In short, a venous blood sample was
collected in a lithium heparin tube (Vacuette, #455084) and thereafter 100 µL of
blood were aliqoted and placed on ice for 10 min. Samples were then stimulated
with PMA for exactly 10 min at 37 °C, followed by 10 min incubation with the
fluorogenic substrate dihydrorhodamine (DHR) 123 at 37 °C, cell lysis and fixation.
Samples were analyzed on a flow cytometer (FACSCalibur, BD and Attune Nxt,
Thermo Fisher). Gating strategy is shown in Supplementary Fig. 7.
Blood cell isolation and macrophage differentiation. For neutrophil isolation,
fresh whole blood was mixed with Lympholyte-poly (Cedarlane #CL5070) at a 1:1
ratio, following the manufacturer’s instructions. Thereafter, the sample was cen-
trifuged at 500×g for 35 min and the polymorphonuclear cell layer was extracted by
pipetting and resuspended in PBS+ 2%FBS. For PBMC isolation, 25 mL of fresh
whole blood was added to 15 mL Ficoll-Paque PLUS (GE Healthcare, #17-1440-03)
in a SepMate tube (STEMCELL Technologies, #15450). Then, the sample was
centrifuged at 1200×g for 10 min. The plasma layer was discarded and the PBMC
layer transferred to a fresh tube followed by washes in PBS+ 2% FBS.
Untouched monocytes were purified from PBMC preparations using the
Monocyte Isolation Kit II (Miltenyi, #130-091-153) following the manufacturer’s
instructions. Labeled samples were run on MS columns, and both the flow-through
(consisting of untouched monocytes), and column bound lymphocytes (mainly B-,
T-, and NK-cells) were collected as well for western blot analysis.
Monocyte-derived macrophages were generated by culturing monocytes for
6 days in X-vivo medium (Lonza, #04744Q) supplemented with Glutamax
(Thermo Fisher, #35050038), Sodium Pyruvate (Thermo Fisher, #11360039), 50
ng/mL M-CSF (Miltenyi, #130-091-153). Fresh medium was added to cells on day
3 and on day 5 media were aspirated and replaced with the same media with 50 ng/
mL IFN-g (Thermo Fisher, #PHC4031). Cells were collected on day 6 for western
blot analysis.
Western blot analysis. Cell pellets were lysed in 100 µL RIPA buffer (150 mM
NaCl, 1% Triton X-100, 0.5% sodiumdeoxycholate, 0.1% SDS, 50 mM Tris, pH 8)
with halt protease and phosphatase inhibitor (Thermo Fisher, #78445) and incu-
bated for 10 min on ice. Following brief sonication, samples were spun at 14,000×g
for 15 min at 4 °C. The supernatant was transferred to a fresh tube and the protein
content of lysates was determined by BCA assay (Thermo Fisher, #23227). Samples
were mixed with NuPAGE LDS sample buffer (Thermo Fisher, #B0007) and
reducing agent (Thermo Fisher, #B0009), heated for 10 min at 70 °C and loaded on
a 4–12% BT bolt plus gel (Thermo Fisher, #NW04120BOX). The gel was equili-
brated for 5 min in 20% EtOH and transferred onto a nitrocellulose membrane
(Thermo Fisher, # IB23002) with iBlot 2 (Thermo Fisher) running the P0 program.
Following the transfer, membranes were re-hydrated in PBS for 5 min and after
that blocked in Odyssey blocking buffer (LI-COR, #92740000). Blots were incu-
bated with primary antibodies overnight at 4 °C in Odyssey blocking buffer+
0.05% Tween 20. Antibodies used were, anti-gp91phox at 1:1000 (Santa Cruz, #sc-
130543), anti-C17orf62 at 1:1000 (Atlas Antibodies, #HPA045696), anti-beta-actin
at 1:2500 (Biotechne, #MAB8929), anti-beta-actin at 1:5000 (Cell Signaling, #4970),
anti-mouse IgG (H+L) IRDye 800CW at 1:10,000 (LI-COR, #926–32212), anti-
rabbit IgG (H+L) IRDye680RD at 1:10,000 (LI-COR, #926–68073), and anti-rabbit
IRDye 800CW at 1:10,000 (LI-COR, #925–32211). Membranes were scanned with
Odyssey CLx and subsequent analysis performed in the image studio software (LI-
COR). Uncropped blots are provided as Supplementary Fig. 8 and 9.
Data availability
Our previously described Icelandic population whole-genome sequence data9 have
been deposited at the European Variant Archive under accession PRJEB15197. The
authors declare that the data supporting the findings of this study are available
within the article, its supplementary information files and upon request. The
HGNC accepted our application for the gene symbol CYBC1 instead of the
placeholder C17orf62 on February 26th 2018, listed under accession 28672.
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